Self-assembling polymeric nanocarriers to target inflammatory lesions in ulcerative colitis

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Gastroenterology

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
• Current treatments for UC have limitations in efficacy and side effects.
• Targeted drug delivery to inflammatory lesions remains a challenge.

Purpose of the Study:

• To develop and evaluate a self-assembling polymeric nanocarrier for localized delivery of Cyclosporine A (CsA).
• To assess the therapeutic efficacy and safety of CsA-loaded nanocarriers in a colitis model.

Main Methods:

• Development of a self-assembling polymeric nanocarrier system.
• Loading of CsA into the nanocarrier, achieving high drug loading capacity.
• Administration of nanocarriers in a trinitrobenzene-sulfonic acid (TNBS)-induced colitis model in animals.
• Quantification of tissue and plasma drug levels.
• Assessment of inflammation scores and colon histology.

Main Results:

• The nanocarrier demonstrated efficient targeting of CsA to inflamed tissue in a TNBS-induced colitis model.
• Tissue drug levels were significantly higher in colitis animals compared to controls, with no detectable plasma drug.
• A CsA dose of 1mg/mL via nanocarrier resulted in significant reduction of inflammation.
• Therapeutic efficacy was comparable to 5-aminosalicylic acid (5-ASA).
• No adverse effects on colon histology were observed in healthy animals after repetitive treatment.

Conclusions:

• Self-assembling polymeric nanocarriers provide a promising strategy for localized delivery of CsA to treat ulcerative colitis.
• This approach enhances drug accumulation at the site of inflammation while minimizing systemic exposure.
• The developed nanocarrier system is well-tolerated and therapeutically effective.